Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9427
Peer-review started: July 1, 2016
First decision: August 8, 2016
Revised: August 18, 2016
Accepted: September 6, 2016
Article in press: September 6, 2016
Published online: November 14, 2016
Processing time: 135 Days and 0.2 Hours
To clarify the prevalence of occult hepatitis B virus (HBV) infection (OBI) and the association between OBI and liver disease progression, defined as development of liver cirrhosis or hepatocellular carcinoma (HCC), worsening of Child-Pugh class, or mortality in cases of chronic hepatitis C virus (HCV) infection.
This prospective cohort study enrolled 174 patients with chronic HCV infection (chronic hepatitis, n = 83; cirrhosis, n = 47; HCC, n = 44), and evaluated disease progression during a mean follow-up of 38.7 mo. OBI was defined as HBV DNA positivity in 2 or more different viral genomic regions by nested polymerase chain reaction using 4 sets of primers in the S, C, P and X open reading frame of the HBV genome.
The overall OBI prevalence in chronic HCV patients at enrollment was 18.4%, with 16.9%, 25.5% and 13.6% in the chronic hepatitis C, liver cirrhosis and HCC groups, respectively (P = 0.845). During follow-up, 52 patients showed disease progression, which was independently associated with aspartate aminotransferase > 40 IU/L, Child-Pugh score and sustained virologic response (SVR), but not with OBI positivity. In 136 patients who were not in the SVR state during the study period, OBI positivity was associated with neither disease progression, nor HCC development.
The prevalence of OBI in chronic HCV patients was 18.4%, and OBI was not associated with disease progression in South Koreans.
Core tip: Whether occult hepatitis B virus (HBV) infection affects the outcomes of chronic hepatitis C virus infection is controversial. This prospective observational study aimed to clarify the association between occult HBV infection and liver disease progression defined as development of liver cirrhosis, worsening of Child-Pugh class, hepatocellular carcinoma or mortality in patients with chronic hepatitis C infection in South Korea.